Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system

World Journal of Gastroenterology

Volumn 11, Issue 39, 2005, Pages 6125-6129

  Zhu, Qiang ^a   Liu, Ji Yong ^a   Xu, Hong Wei ^a   Yang, Chong Mei ^a   Zhang, An Zhong ^a   Cui, Yi ^a   Wang, Hong Bo ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Colon neoplasm; Fas system; Immune counterattack

Indexed keywords

CD45 ANTIGEN; FAS ANTIGEN; FAS LIGAND; MESSENGER RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER TISSUE; CELL COUNT; CELL DEATH; CELL INTERACTION; COCULTURE; COLORECTAL CANCER; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; IN SITU HYBRIDIZATION; LYMPHOCYTIC INFILTRATION; NICK END LABELING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; TUMOR ESCAPE;

EID: 30644481120     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i39.6125     Document Type: Article

References (15)

1. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449-1456
2. Maher S, Toomey D, Condron C, Bouchier-Hayes D. Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack. Immunol Cell Biol 2002; 80: 131-137
3. Perabo FG, Kamp S, Schmidt D, Lindner H, Steiner G, Mattes RH, Wirger A, Pegelow K, Albers P, Kohn EC, von Ruecker A, Mueller SC. Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation. Br J Cancer 2001; 84: 1330-1338
4. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, Debatin KM, Krammer PH. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245: 301-305
5. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989; 169: 1747-1756
6. Krishnakumar S, Kandalam M, Mohan A, Iyer A, Venkatesan N, Biswas J, Shanmugam MP. Expression of Fas ligand in retinoblastoma. Cancer 2004; 101: 1672-1676
7. Abrams SI. Positive and negative consequences of Fas/Fas ligand interactions in the antitumor response. Front Biosci 2005; 10: 809-821
8. Houston A, Bennett MW, O'Sullivan GC, Shanahan F, O'Connell J. Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-beta expression. Br J Cancer 2003; 89: 1345-1351
9. Okada K, Komuta K, Hashimoto S, Matsuzaki S, Kanematsu T, Koji T. Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis. Clin Cancer Res 2000; 6: 3560-3564
10. Ohta T, Elnemr A, Kitagawa H, Kayahara M, Takamura H, Fujimura T, Nishimura G, Shimizu K, Yi SQ, Miwa K. Fas ligand expression in human pancreatic cancer. Oncol Rep 2004; 12: 749-754
11. Hallermalm K, De Geer A, Kiessling R, Levitsky V, Levitskaya J. Autocrine secretion of Fas ligand shields tumor cells from Fas-mediated killing by cytotoxic lymphocytes. Cancer Res 2004; 64: 6775-6782
12. Strand S, Vollmer P, van den Abeelen L, Gottfried D, Alla V, Heid H, Kuball F, Theobald M, Galle PR, Strand D. Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells. Oncogene 2004; 23: 3732-3736
13. Kase S, Osaki M, Adachi H, Kaibara N, Ito H. Expression of Fas and Fas ligand in esophageal tissue mucosa and carcinomas. Int J Oncol 2002; 20: 291-297
14. Lee SH, Shin MS, Lee HS, Bae JH, Lee HK, Kim HS, Kim SY, Jang JJ, Joo M, Kang YK, Park WS, Park JY, Oh RR, Han SY, Lee JH, Kim SH, Lee JY, Yoo NJ. Expression of Fas and Fas-related molecules in human hepatocellular carcinoma. Hum Pathol 2001; 32: 250-256
15. Kim R, Emi M, Tanabe K, Uchida Y, Toge T. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer 2004; 100: 2281-22891